Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.39 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.39 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.39 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.39 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.39 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.39 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18342498 | 1.00 | CYP1A2 (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Hydrochloric Acid SCHEMBL3471974 | 1.00 | CYP1A2 (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL5571470 | 0.98 | CYP1A2 (0.45) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL5571472 | 0.98 | CYP1A2 (0.45) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL9219251 | 0.98 | CYP1A2 (0.45) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Hydrochloric Acid SCHEMBL3816765 | 0.85 | ALOX15 (0.44) | SLC1A3SLC1A2SLC1A1BLM | |
| SCHEMBL16240446 | 0.82 | ALOX15 (0.45) | GRIK1SLC1A3SLC1A2SLC1A1GRIK2 | |
| SCHEMBL16240444 | 0.82 | ALOX15 (0.45) | GRIK1SLC1A3SLC1A2SLC1A1GRIK2 | |
| Hydrochloric Acid SCHEMBL918666 | 0.79 | TDP1 (0.37) | FOLH1 | |
| Hydrochloric Acid SCHEMBL19384699 | 0.79 | TDP1 (0.37) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | disclosed |
| US-20260007785-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | disclosed |
| WO-2024230246-A1 | POLYPEPTIDE RADIONUCLIDE COMPLEX TARGETING FIBROBLAST ACTIVATION PROTEIN AND USE THEREOF | 成都纽瑞特医疗科技股份有限公司 | 2024-11-14 | — | — | WO | disclosed |
| CN-118930606-A | Polypeptide radionuclide complex targeting fibroblast activation protein and application thereof | 成都纽瑞特医疗科技股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240350680-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2024-10-24 | — | — | US | disclosed |
| EP-4374924-A2 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| US-11951190-B2 | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer | NOVARTIS AG (CH) | 2024-04-09 | — | — | US | disclosed |
| US-11931430-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| EP-4095130-B1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2024-01-31 | — | — | EP | disclosed |
| US-20230406847-A1 | LIGANDS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) CONTAINING HETEROAROMATIC LINKER BUILDING BLOCKS | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2023-12-21 | — | — | US | disclosed |
| US-5728868-A | Prodrugs of protein tyrosine kinase inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-17 | — | — | US | disclosed |
| EP-0804413-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-11-05 | — | — | EP | disclosed |
| US-5561133-A | Thymidylate synthase inhibiting quinazolinones | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1996-10-01 | — | — | US | disclosed |
| WO-1996022277-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-25 | — | — | WO | disclosed |
| EP-0711177-A1 | IMPROVEMENTS RELATING TO PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| EP-0708660-A1 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995003830-A2 | PRODRUGS OF FARNESYL TRANSFERASE INHIBITORS FOR ADEPT OR VDEPT | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| WO-1995002420-A2 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD. (GB) | 1995-01-26 | — | — | WO | disclosed |
| EP-0631576-A1 | DIPEPTIDYLQUINAZOLONES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1995-01-04 | — | — | EP | disclosed |
| WO-1993019051-A1 | DIPEPTIDYLQUINAZOLONES AS ANTI-CANCER AGENTS | BRITISH TECHNOLOGY GROUP LTD (GB) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406847-A1 | LIGANDS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) CONTAINING HETEROAROMATIC LINKER BUILDING BLOCKS | KLK3, FOLH1, BPHL | GABRP 611/4885GABRD 1814/4885GABRA1 1372/4885 |
| US-11951190-B2 | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | GABRP 899/4885GABRD 3892/4885GABRA1 2211/4885 |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, PSMA1, ACP3 | GABRP 1260/4885GABRD 2594/4885GABRA1 1315/4885 |
| US-11931430-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | GABRP 970/4885GABRD 4202/4885GABRA1 2420/4885 |
| US-20240350680-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, FOLH1, PSMA1 | GABRP 970/4885GABRD 4202/4885GABRA1 2420/4885 |
| US-20260007785-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | PSMA1, ACP3, FOLH1 | GABRP 1653/4885GABRD 2992/4885GABRA1 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.